S-3 filed Jun 26, 2026 at 17:21 ET
Indaptus Therapeutics filed an S-3 registration statement to allow selling stockholders (Ting Yang, Lina Deng, and David Lazar) to resell up to 18,864,000 shares of common stock, representing approximately 14.2% of outstanding shares. The company will not receive any proceeds. This filing comes amid a severe operational crisis: the company has discontinued all clinical development of its lead candidate Decoy20, has no active programs, and its auditor has expressed substantial doubt about its ability to continue as a going concern. The resale registration creates significant overhang and facilitates insider selling, compounding the fundamental distress.